Welcome to our dedicated page for Core One Labs news (Ticker: CLABF), a resource for investors and traders seeking the latest updates and insights on Core One Labs stock.
Core One Labs Inc. (CLABF) is a biotechnology innovator advancing psychedelic-assisted therapies through proprietary research and novel delivery systems. This page serves as the definitive source for verified updates on the company's scientific progress, regulatory milestones, and strategic initiatives.
Investors and industry professionals will find essential information about CLABF's developments in psilocybin formulations, preclinical study results, and intellectual property advancements. Our curated news collection covers clinical research updates, partnership announcements, and technology innovations targeting neurological disorders.
Key focus areas include breakthrough therapies for Alzheimer's, Parkinson's, and treatment-resistant depression, supported by peer-reviewed study data. Bookmark this resource to stay informed about CLABF's progress in reshaping mental healthcare through evidence-based psychedelic medicine.
Core One Labs Inc. (OTCQB:CLABF) has marked a significant milestone with the successful synthetic production of psilocin at its GMP facility, achieved by its subsidiary Awakened Biosciences Inc.. This development showcases operational synergies from a recent acquisition, enhancing the company's strategic goal of becoming a large-scale supplier of psychedelic compounds. CEO Joel Shacker emphasized that this achievement is foundational for future production and research of psilocybin and other psychedelic compounds. The production was led by Dr. Tony Durst, a specialist in medicinal chemistry, who aims to advance innovations in psychedelics research. Awakened currently holds three provisional patents for psilocybin production methods, further solidifying Core One's position in the emerging psychedelics market.
